Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during the first administration to healthy male subjects

被引：0
|
作者：
Nunes, T. [1 ]
Rocha, J. -F. [1 ]
Pinto, R. [1 ]
Machado, R. [1 ]
Wright, L. [1 ]
Falcao, A. [2 ]
Almeida, L. [3 ]
Soares-da-Silva, P. [1 ,4 ]
机构：
[1] BIAL Portela & Ca SA, Res & Dev, Sao Mamede do Coronado, Portugal
[2] Univ Coimbra, Fac Pharm, P-3000 Coimbra, Portugal
[3] Univ Aveiro, Hlth Sci Sect, Aveiro, Portugal
[4] Univ Porto, Fac Med, Dept Pharmacol & Therapeut, Oporto, Portugal
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2012年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during multiple rising dose regimens in healthy male subjects
    Rocha, J. -F.
    Nunes, T.
    Vaz-da-Silva, M.
    Machado, R.
    Wright, L.
    Falcao, A.
    Almeida, L.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 696 - 696
  • [2] Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
    Almeida, Luis
    Rocha, Jose Francisco
    Falca, Amilcar
    Nuno Palma, P.
    Loureiro, Ana I.
    Pinto, Roberto
    Bonifacio, Maria Joao
    Wright, Lyndon C.
    Nunes, Teresa
    Soares-da-Silva, Patricio
    CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 139 - 151
  • [3] Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans
    Luis Almeida
    Patrício Soares-da-Silva
    Drugs in R & D, 2003, 4 (4) : 207 - 217
  • [4] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
    Yoon, Seonghae
    Shin, Donghoon
    Lee, Howard
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5033 - 5049
  • [5] PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF LC350189, A NOVEL XANTHINE OXIDASE INHIBITOR, IN HEALTHY SUBJECTS
    Yoon, S.
    Moon, S.
    Jang, K.
    Jang, I.
    Lim, K.
    Yu, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S94 - S94
  • [6] Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
    Gillen, Michael
    Miner, Jeffrey N.
    Valdez, Shakti
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Stangier, Joachim
    Rathgen, Karin
    Staehle, Hildegard
    Gansser, Dietmar
    Roth, Willy
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (03) : 292 - 303
  • [8] Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
    Gillen, Michael
    Shen, Zangong
    Miner, Jeffrey N.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
    Shen, Zancong
    Gillen, Michael
    Miner, Jeffrey N.
    Bucci, Gail
    Wilson, David M.
    Hall, Jesse W.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2077 - 2086
  • [10] Pharmacokinetics and pharmacodynamics of opicapone in healthy Japanese and matched Caucasian subjects
    Rocha, J. -F.
    Falcao, A.
    Lopes, N.
    Santos, A. T.
    Nunes, T.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2014, 29 : S261 - S261
12345